Sound waves could boost brain cancer drug delivery

NCT ID NCT06496971

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether combining the drug Avastin with a focused ultrasound system (NaviFUS) can improve outcomes for people with recurrent glioblastoma, an aggressive brain cancer. The ultrasound temporarily opens the blood-brain barrier to let more drug reach the tumor. About 32 adults who have already had standard treatments will be randomly assigned to get Avastin alone or Avastin plus the ultrasound. The main goal is to see if the combination helps patients live longer without their cancer growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Bevacizumab (Avastin) combined with low-intensity focused ultrasound and microbubbles
What this could lead to
If it works, this could offer a new way to deliver drugs to brain tumors, potentially slowing disease progression in recurrent glioblastoma.
What could go wrong
This is a small early Phase 3 trial with only 32 participants. The approach is experimental, and the added benefit over Avastin alone is uncertain. Risks include side effects from the ultrasound procedure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Linkou Chang Gung Memorial Hospital

    RECRUITING

    Taoyuan, 33305, Taiwan

  • National Taiwan University Hospital

    RECRUITING

    Taipei, 10048, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.